MedPredict
MedPredict Thought Leader Insight
User ID:
Password:
  For Pharma and Biotech Decision-Makers LATEST PUBLICATIONS  

One of your key challenges is to stay on top of the latest activities in your target therapeutic areas. What’s happening with competitive compounds in the pipeline? What are their indications and marketing claims likely to be? How are trends in clinical practice evolving, and how will that affect your current and future business?

MedPredict delivers the insights that will drive your strategic decision-making, but without the big price tag and long lead-time required to conduct your own thought leader interviews or market research. We deliver a wide range of syndicated reports that are ready to download today, so you can act on the information right away. And if you don't see what you need in our syndicated reports database, we would be happy to provide you with a customized proposal for proprietary research.

  • >1,000 top tier global thought leaders participate on our proprietary panels
  • >30 indications covered
  • >40 specialties covered

Browse our site to see how MedPredict can provide the thought leader insight you need to make breakthrough strategic decisions.

Reports Coming Soon...

Breast Cancer

Respiratory

Rheumatoid Arthritis

Osteoporosis

Pain

Psoriasis

 

 

 

 

Anticoagulants Post-ASH This Panel continues where our last report left off, exploring the revolutionary use of antithrombotics and antiplatelets for use in the prevention of ischemic events during/after surgery, acute coronary syndrome, secondary prevention venous thromboembolism and secondary prevention for atrial fibrillation. learn more >>

Malignant Hematology Post-ASH This report captures the opinions of 7 North American experts in malignant hematology. They provide insight into the practice-changing ramifications of the data presented at ASH 2009, relevant to multiple myeloma, myelodysplastic syndrome, acute myelogenous leukemia, chronic myelogenous leukemia and lymphoma. learn more >>

Rheumatoid Arthritis Post-ACR Debrief This report is based on 6 interviews conducted with American and European rheumatology thought leaders following the American College of Rheumatology (ACR) 2009 meeting. The Panel highlights key learnings from the meeting, focusing on data that suggests any advantage for newer biologicals and small molecules compared to the standards of care for the treatment of rheumatoid arthritis. The Thought Leaders also provide insight into divergent activities and results pertaining to lupus, vasculitis, polymyositis and scleroderma. learn more >>

 
bottom.gif